Handelsinvest Investeringsforvaltning Sells 4,432 Shares of Qiagen (NYSE:QGEN)

Handelsinvest Investeringsforvaltning lowered its position in shares of Qiagen (NYSE:QGEN) by 36.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,829 shares of the company’s stock after selling 4,432 shares during the quarter. Handelsinvest Investeringsforvaltning’s holdings in Qiagen were worth $337,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Lindbrook Capital LLC increased its holdings in Qiagen by 21.6% in the fourth quarter. Lindbrook Capital LLC now owns 1,335 shares of the company’s stock valued at $58,000 after purchasing an additional 237 shares during the last quarter. Xponance Inc. increased its holdings in Qiagen by 2.7% in the fourth quarter. Xponance Inc. now owns 9,609 shares of the company’s stock valued at $417,000 after purchasing an additional 253 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in Qiagen by 66.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 710 shares of the company’s stock valued at $31,000 after purchasing an additional 283 shares during the last quarter. CWM LLC increased its holdings in Qiagen by 19.1% in the first quarter. CWM LLC now owns 2,236 shares of the company’s stock valued at $96,000 after purchasing an additional 358 shares during the last quarter. Finally, Eagle Asset Management Inc. increased its holdings in Qiagen by 2.2% in the fourth quarter. Eagle Asset Management Inc. now owns 20,338 shares of the company’s stock valued at $883,000 after purchasing an additional 430 shares during the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Stock Down 0.3 %

QGEN stock opened at $40.58 on Thursday. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.84 and a quick ratio of 1.45. The stock has a market capitalization of $9.26 billion, a P/E ratio of 27.21, a P/E/G ratio of 3.15 and a beta of 0.40. The business has a 50-day moving average of $43.16 and a 200-day moving average of $43.49. Qiagen has a fifty-two week low of $34.74 and a fifty-two week high of $47.70.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Monday, April 29th. The company reported $0.46 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.02. Qiagen had a return on equity of 12.59% and a net margin of 17.38%. The company had revenue of $459.00 million during the quarter, compared to analysts’ expectations of $453.91 million. During the same period in the prior year, the firm earned $0.53 earnings per share. Qiagen’s revenue for the quarter was down 5.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Qiagen will post 2.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

QGEN has been the subject of a number of recent analyst reports. Wolfe Research upgraded Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price objective for the company in a report on Thursday, June 27th. Stifel Nicolaus lowered their price target on Qiagen from $55.00 to $45.00 and set a “hold” rating for the company in a report on Wednesday, May 1st. Finally, JPMorgan Chase & Co. increased their price target on Qiagen from $52.00 to $54.00 and gave the stock an “overweight” rating in a report on Tuesday, June 18th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $51.05.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.